InvestorsHub Logo
Followers 90
Posts 17400
Boards Moderated 0
Alias Born 09/06/2006

Re: inveterate post# 483567

Monday, 06/06/2022 3:37:13 PM

Monday, June 06, 2022 3:37:13 PM

Post# of 699981

Is anyone familiar with this cancer treatment?


Dostarlimab is a CI, specifically a PD-1 blocker.

100% CR is fantastic. It was in patients with mismatch-repair deficiency though, and we already know those are very responsive to PD-(L)1 agents.

I doubt the CI is really much different from the other PD-1s. Same MOA.

Still a nice commercial win as that will be very pretty label.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News